Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 6;24(14):1883–1891. doi: 10.1177/1352458517735190

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2017

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — Forest plot for proportion of patients with clinically meaningful worsening in 29-Item Multiple Sclerosis Impact Scale physical impact subscale score at week 96 for daclizumab beta versus IM IFN beta-1a by baseline demographics and disease characteristics.

^aOnly patients with available baseline assessment were included in the overall MSIS-29 PHYS analysis.

^bPatients included in the overall MSIS-29 PHYS analysis with missing baseline Gd⁺ lesions data: IM IFN beta-1a, n = 12; daclizumab beta, n = 17.

^cPatients included in the overall MSIS-29 PHYS analysis with missing baseline T2 hyperintense lesion volume data: IM IFN beta-1a, n = 13; daclizumab beta, n = 17.

^dPatients included in the overall MSIS-29 PHYS analysis missing baseline disease activity data: IM IFN beta-1a, n = 4; daclizumab beta, n = 11.